Добірка наукової літератури з теми "Targeted nanotherapy"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Targeted nanotherapy".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Targeted nanotherapy":
Kim, Gloria J., and Shuming Nie. "Targeted cancer nanotherapy." Materials Today 8, no. 8 (August 2005): 28–33. http://dx.doi.org/10.1016/s1369-7021(05)71034-8.
Mathew, Anila, Toru Maekawa, and D. Sakthikumar. "Aptamers in Targeted Nanotherapy." Current Topics in Medicinal Chemistry 15, no. 12 (April 17, 2015): 1102–14. http://dx.doi.org/10.2174/1568026615666150413153525.
Zhu, Peng, Carl Atkinson, Suraj Dixit, Qi Cheng, Danh Tran, Kunal Patel, Yu-Lin Jiang, et al. "Organ preservation with targeted rapamycin nanoparticles: a pre-treatment strategy preventing chronic rejection in vivo." RSC Advances 8, no. 46 (2018): 25909–19. http://dx.doi.org/10.1039/c8ra01555d.
Crintea, Andreea, Anne-Marie Constantin, Alexandru C. Motofelea, Carmen-Bianca Crivii, Maria A. Velescu, Răzvan L. Coșeriu, Tamás Ilyés, Alexandra M. Crăciun, and Ciprian N. Silaghi. "Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer." Journal of Functional Biomaterials 14, no. 9 (September 9, 2023): 466. http://dx.doi.org/10.3390/jfb14090466.
Narayanan, Sreeja, N. S. Binulal, Ullas Mony, Koyakutty Manzoor, Shantikumar Nair, and Deepthy Menon. "Folate targeted polymeric ‘green’ nanotherapy for cancer." Nanotechnology 21, no. 28 (June 28, 2010): 285107. http://dx.doi.org/10.1088/0957-4484/21/28/285107.
Katsogiannou, M., L. Peng, C. V. Catapano, and P. Rocchi. "Active-Targeted Nanotherapy Strategies for Prostate Cancer." Current Cancer Drug Targets 11, no. 8 (October 1, 2011): 954–65. http://dx.doi.org/10.2174/156800911797264770.
Metcalfe, Su M., and Tarek M. Fahmy. "Targeted nanotherapy for induction of therapeutic immune responses." Trends in Molecular Medicine 18, no. 2 (February 2012): 72–80. http://dx.doi.org/10.1016/j.molmed.2011.11.002.
Hu, Xiankang, and Jianxiang Zhang. "Yeast capsules for targeted delivery: the future of nanotherapy?" Nanomedicine 12, no. 9 (May 2017): 955–57. http://dx.doi.org/10.2217/nnm-2017-0059.
Rapoport, N. Ya, K. H. Nam, Z. Gao, and A. Kennedy. "Application of ultrasound for targeted nanotherapy of malignant tumors." Acoustical Physics 55, no. 4-5 (July 18, 2009): 594–601. http://dx.doi.org/10.1134/s1063771009040162.
Soodgupta, Deepti, Dipanjan Pan, Grace Hu, Angana Senpan, Xiaoxia Yang, Katherine N. Weilbaecher, Edward V. Prochownik, Gregory M. Lanza, and Michael H. Tomasson. "Preclinical Development Of a Nanomedicne Approach For Multiple Myeloma Targeting The Myc Oncoprotein." Blood 122, no. 21 (November 15, 2013): 4228. http://dx.doi.org/10.1182/blood.v122.21.4228.4228.
Дисертації з теми "Targeted nanotherapy":
Sibuyi, Nicole Remaliah Samantha. "Development of a receptor targeted nanotherapy using a proapoptotic peptide." University of the Western Cape, 2015. http://hdl.handle.net/11394/4708.
The prevalence of obesity amongst South Africans is alarming, with more than 29% of men and 56% of women considered to be obese. Angiogenesis, a process for development of new blood vessels play a major role in growth and survival of the adipose tissues. Pharmacological inhibitors of angiogenesis are therefore a sensible strategy to reduce excess body weight. Current anti-obesity drugs have limitations because of their lack of selectivity and specificity, which lead to undesirable side effects and reduced drug efficacy. Future anti-obesity therapeutic strategies should be target-specific, with minimal toxicity towards healthy tissues will be more appropriate for obesity treatment. Targeted nano-therapeutic agents are currently being developed to overcome the drawbacks associated with conventional drug therapies. The nano-based delivery vehicles that specifically target diseased cells are appealing as they could reduce drug toxicity towards healthy tissues and be more effective at lower dosages. The main aim of this study was to develop a receptor-mediated nanotherapy that specifically targets the white adipose tissue vasculature and trigger the death of these cells through apoptosis. The 14 nm gold nanoparticles (AuNPs) were synthesized using theTurkevich method following reduction of gold aurate by sodium citrate salt. Different chemistries were used to functionalise the AuNPs for biological application by conjugating with either vascular targeting peptide or pro-apoptotic peptide on their surface or both. The nanomaterials were characterised by UV-Vis, Zeta potential and transmission electron microscopy (TEM). The sensitivity and specificity of various AuNP conjugates were tested in vitro on colon and breast cancer cell lines. A human (Caco-2) cell line that expresses the receptor for the adipose homing peptide was chosen as an in vitro model system. Cellular toxicity and uptake of the nanoparticles was evaluated using the WST-1 assay, Inductively Coupled Plasma-Optical Emission Spectra (ICP-OES) and TEM. The induction of apoptosis following exposure to the nanoparticles was examined by Western blot and flow cytometric analysis. The anti-proliferative activity of the targeted therapeutic nanoparticles on the cells was more pronounced on the cells expressing the receptor for the adipose homing peptide. The uptake of unfunctionalised AuNPs was higher compared to functionalised nanoparticles, but this did not impair cell viability. The activity of the therapeutic peptide was retained and enhanced following conjugation to AuNPs as shown by Western blot and flow cytometric analysis. The nanotherapy under study demonstrated receptor mediated targeting, and enhanced activity on the cells expressing the receptor. However, the therapeutic and efficacy of the targeted nanotherapy still need to be tested in animal models of obesity to confirm the treatment specificity.
Webster, Carl. "Development of a novel targeted nanotherapy for the treatment of melanoma." Thesis, University of East Anglia, 2016. https://ueaeprints.uea.ac.uk/62677/.
Journaux-Duclos, Justine. "Ciblage thérapeutique de l'adénocarcinome pancréatique par hyperthermie magnétique ou ablation magnéto-mécanique." Electronic Thesis or Diss., Toulouse 3, 2023. http://www.theses.fr/2023TOU30360.
Due to their physico-chemical properties, magnetic iron oxide nanoparticles (SPION) offer many advantages. They are biocompatible and functionalizable and therefore have already been used as a contrast agent for MRI diagnosis. They can respond to the application of magnetic fields: release thermal energy in response to the application of a high frequency alternating magnetic field (AMF), or generate mechanical forces when they are exposed to low frequency rotating magnetic fields (RMF). Clinical trials using magnetic hyperthermia mediated by SPION and AMF fields have been carried out on glioblastoma and prostate cancer in association with radiotherapy. Nevertheless, the benefit on life expectancy was negligible and adverse effects were noted on adjacent healthy tissues. But our team has previously shown that it is possible to specifically induce tumor cells and microenvironment cells death through the use of low concentrations of targeted magnetic nanoparticle that specifically accumulate in the lysosomes of the targeted cells. Then AMF fields specifically induce the death of target cells by targeted intra-lysosomal magnetic hyperthermia MILH. The mechanisms leading to the death of these cells have been characterized and show that it is initiated in the lysosomes by the generation of ROS according to the Fenton reaction which requires Fe ions and can be catalyzed by an acid pH and an increase of temperature (optimal at 40°C). However, the origin of the Fe ions involved in the Fenton reaction has not been elucidated. Another strategy was also established in the team; it is based on the application of RMF fields which will generate mechanical forces from the SPIONs and induce cell death by targeted intra-lysosomal mechanical ablation. We have chosen as a model, the pancreatic adenocarcinoma particularly resistant to conventional therapies and characterized by the presence of a large and dense microenvironment. In this microenvironment, CAFs (Cancer Associated Fibroblasts) play a key role, in particular through the secretion of extracellular matrix and soluble molecules, limiting the penetration and effectiveness of treatments and contributing to the acquisition of resistance. Cancer cells as well as CAF can overexpress the cholecystokinin receptor type 2 (RCCK2). This membrane receptor has the property of internalizing after binding of its specific agonist: the gastrin. The team has developed functionalized nanoparticles with high heating power vectorized with gastrin peptides (NF@Gastrin). These nanoparticles specifically recognize human pancreatic MiaPaca2 cells and CAFs expressing the CCK2 receptor and accumulate in their lysosomes. The application of AMF (275 kHz, 30 mT) or RMF (1 Hz, 40 mT) fields specifically induces the death of these cells by MILH or targeted intra-lysosomal mechanical ablation. First, we compared the effects of MILH induced by NF@Gastrin to those induced by the same nanoparticles covered with a hermetic silica shell (NF@SiO2@Gastrin), preventing the release of iron under the application of AMF field, in the presence or absence of Ferristatin-II, an inhibitor of iron uptake by the cell. This study demonstrate that the iron involved in the Fenton reaction at the origin of ROS production by MILH came from the endogenous pool of the cell and not from the release of iron by the iron oxide nanoparticles submitted to AMF. Then, we demonstrate that MILH and mechanical ablation increase the expression of damage-associated molecular patterns (DAMPs) on the surface of MiaPaca2 cells and CAFs having specifically internalized NF@Gastrin and stimulate their phagocytosis by macrophages. These two approaches, magnetic hyperthermia and mechanical ablation, could therefore be two new strategies to restore anti-tumor immunity in pancreatic adenocarcinoma. Finally, these two strategies can also modify the pro-tumoral phenotype of CAFs, by inhibiting their migration, decreasing their collagen secretion
Gouveia, Virgínia Adorinda Moura. "Target-to-treat nanotherapy for rheumatoid arthritis." Doctoral thesis, 2020. https://hdl.handle.net/10216/128621.
Gouveia, Virgínia Adorinda Moura. "Target-to-treat nanotherapy for rheumatoid arthritis." Tese, 2020. https://hdl.handle.net/10216/128621.
Частини книг з теми "Targeted nanotherapy":
Sahu, Prashant, Sushil K. Kashaw, Varsha Kashaw, and Arun K. Iyer. "Functional Nanogels and Hydrogels: A Multipronged Nanotherapy in Drug Delivery and Imaging." In Multifunctional And Targeted Theranostic Nanomedicines, 241–70. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-0538-6_11.
Ueoka, Ryuichi, Yoko Matsumoto, Hideaki Ichihara, and Yuji Komizu. "Membrane-Targeted Nanotherapy with Hybrid Liposomes for Cancer Cells Leading to Apoptosis." In Molecular Science of Fluctuations Toward Biological Functions, 221–44. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55840-8_11.
Derakhshandeh, Katayoun, and Abbas Hemmati Azandaryani. "Active-targeted Nanotherapy as Smart Cancer Treatment." In Smart Drug Delivery System. InTech, 2016. http://dx.doi.org/10.5772/61791.
Prabhakar, Pranav Kumar. "Targeted Nanotherapies for Diabetic Complications." In Cutting-Edge Applications of Nanomaterials in Biomedical Sciences, 178–200. IGI Global, 2023. http://dx.doi.org/10.4018/979-8-3693-0448-8.ch006.
Khusro, Ameer, Chirom Aarti, Mona M. M. Y. Elghandour, and Abdelfattah Z. M. Salem. "Potential targets in quest for new antitubercular drugs: Implications of computational approaches for end-TB strategy." In A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy, 229–60. Elsevier, 2021. http://dx.doi.org/10.1016/b978-0-12-819985-5.00005-x.
Abou-Jaoude, Mathieu, Rakesh Kumar Sharma, Aditya Nair, Manoj J. Mammen, Ravikumar Aalinkeel, Stanley A. Schwartz, and Supriya D. Mahajan. "Nanotherapy approach to target ZIKA virus in microglia: A case study." In Nanotechnological Applications in Virology, 113–28. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-323-99596-2.00013-3.
Тези доповідей конференцій з теми "Targeted nanotherapy":
Bonizzi, Arianna, Marta Truffi, Leopoldo Sitia, Serena Mazzucchelli, Sara Negri, Luca Sorrentino, Marta Sevieri, and Fabio Corsi. "Development FAP-Targeted Nanotherapy against Cancer-Associated Fibroblasts." In The 7th World Congress on Recent Advances in Nanotechnology. Avestia Publishing, 2022. http://dx.doi.org/10.11159/nddte22.141.
Mriouah, Jihane, Rae Lynn Nesbitt, Susan Richter, Melinda Wuest, Desmond Pink, Deborah Sosnowski, Roy Duncan, Frank Wuest, Andries Zijlstra, and John Lewis. "Abstract 5143: Fusogenic targeted liposomes: novel nanotherapy for specific treatment of prostate cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5143.
Baldwin, Paige, Rajiv Kumar, and Srinivas Sridhar. "Abstract 3715: Targeted nanotherapy using the PARP inhibitor talazoparib for breast cancer treatment." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3715.
Heller, Daniel A., Edgar Jaimes, Ryan Williams, and Janki Shah. "Abstract 2032: Renal tubule-targeted supportive care nanotherapy for cisplatin-induced acute kidney injury." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-2032.